Gynecologic Oncology Practice Questions

Q: A 35-year-old pregnant patient is at the highest risk for the concurrent development of which of the following malignancies?

Cervix. **Explanation:** **Cervical cancer** is the most common gynecological malignancy diagnosed during pregnancy. This is primarily because the peak incidence of cervical cancer (30–40 years) overlaps significantly with the reproductive years. Routine prenatal care often involves a pelvic examination and Pap smear, leading to increased detection of cervical dysplasia or early-stage carcinoma in pregnant women. **Analysis of Options:** * **A. Cervix (Correct):** It accounts for nearly 70-80% of all gynecological cancers associated with pregnancy. The incidence is approximately 1 to 10 per 10,000 pregnancies. * **B. Ovary:** Ovarian cancer is the second most common gynecological malignancy in pregnancy. While adnexal masses are frequently found on routine ultrasound, most are functional cysts (like corpus luteum) or benign dermoids rather than malignancies. * **C. Uterus:** Endometrial cancer is extremely rare during pregnancy because high levels of progesterone exert a protective effect against the estrogen-driven proliferation of the endometrium. Furthermore, the presence of a malignancy in the uterine lining usually precludes successful implantation. * **D. Vagina:** Primary vaginal cancer is rare in the general population and exceptionally rare in the pregnant age group, as it typically affects postmenopausal women. **High-Yield Clinical Pearls for NEET-PG:** * **Most common non-gynecological cancer in pregnancy:** Breast cancer (followed by melanoma and lymphomas). * **Diagnosis:** Pregnancy does not change the diagnostic criteria for cervical cancer; colposcopy is safe, but endocervical curettage (ECC) is strictly **contraindicated**. * **Management:** For early-stage disease diagnosed in the first trimester, treatment can often be delayed until fetal maturity if the patient desires to continue the pregnancy.

Q: A 18-year-old, sexually active female has no family history of cancer or cardiac disease, and her physical examination is unremarkable. Which of the following screening tests would most benefit this patient?

Pap smear. **Explanation:** The correct answer is **Pap smear**. **Why it is correct:** The primary goal of screening in a young, sexually active female is the early detection of cervical dysplasia. According to standard guidelines (ACOG/FOGSI), cervical cancer screening via a **Pap smear** should generally begin at age 21. However, in the context of this question, the patient is **sexually active**. Since Human Papillomavirus (HPV) infection—the primary driver of cervical cancer—is a sexually transmitted infection, this patient is at risk. Among the options provided, the Pap smear is the only evidence-based screening tool that significantly reduces morbidity and mortality in this demographic by identifying pre-malignant lesions. **Why the other options are incorrect:** * **A. Colonoscopy:** Routine screening for colorectal cancer typically begins at age 45 (or 40 if there is a family history). It is not indicated for an asymptomatic 18-year-old. * **B. Mammography:** Routine screening for breast cancer starts at age 40–50. In an 18-year-old with no family history or palpable mass, mammography is inappropriate due to high breast tissue density and low risk. * **D. Pelvic scan:** Routine pelvic ultrasound is not a recommended screening tool for asymptomatic women. It lacks the sensitivity and specificity to serve as a screening test for ovarian or uterine cancers. **Clinical Pearls for NEET-PG:** * **Cervical Cancer Screening:** In India, the WHO/FOGSI recommends screening from age 30, but for exams, follow the standard rule: Start at **21 years** regardless of the age of onset of sexual activity (though some boards emphasize sexual activity as the trigger). * **Frequency:** Age 21–29: Pap smear every 3 years. Age 30–65: Co-testing (Pap + HPV DNA) every 5 years is preferred. * **HPV Vaccine:** Ideally administered between ages 9–14 (2 doses) or 15–45 (3 doses). It is the most effective primary prevention.

Q: What is the most common malignant ovarian tumor in young individuals?

Dysgerminoma. **Explanation:** The correct answer is **Dysgerminoma**. **1. Why Dysgerminoma is correct:** In the context of ovarian tumors in young individuals (children and adolescents), **Germ Cell Tumors (GCTs)** are the most common category. Among these, while the Benign Cystic Teratoma (Dermoid cyst) is the most common *benign* tumor, the **Dysgerminoma** is the most common **malignant** germ cell tumor. It typically affects women in their teens and early twenties. It is the female counterpart of the testicular seminoma and is highly radiosensitive and chemosensitive. **2. Why other options are incorrect:** * **Dermoid cyst (Benign Cystic Teratoma):** This is the most common ovarian tumor in young women overall, but it is **benign**, not malignant. * **Mucinous cystadenoma:** This is a surface epithelial tumor. Epithelial tumors are the most common ovarian tumors in postmenopausal women but are rare in the young. * **Fibroma:** This is a benign sex cord-stromal tumor. While it can occur at any age, it is not the most common malignancy in this demographic and is associated with Meigs’ Syndrome. **3. NEET-PG High-Yield Pearls:** * **Tumor Marker:** Dysgerminoma is associated with elevated **LDH** (Lactate Dehydrogenase) and sometimes hCG. * **Association:** It is the most common malignancy found in patients with **gonadal dysgenesis** (e.g., Swyer syndrome). * **Microscopy:** Characterized by large, round "fried-egg" cells with central nuclei and fibrous stroma infiltrated with **lymphocytes**. * **Management:** It is highly responsive to the **BEP regimen** (Bleomycin, Etoposide, Platinum).

Q: All of the following may predispose to Endometrial Carcinoma, except:

Oral contraceptive. **Explanation:** The development of Endometrial Carcinoma (specifically Type I) is primarily driven by **unopposed estrogenic stimulation**, which leads to endometrial hyperplasia and subsequent malignancy. **Why Oral Contraceptives (OCPs) are the correct answer:** Combined Oral Contraceptive pills contain both estrogen and **progesterone**. Progesterone counteracts the proliferative effect of estrogen on the endometrium, inducing secretory changes and eventual thinning (atrophy). Long-term use of OCPs is a well-established **protective factor**, reducing the risk of endometrial cancer by approximately 50%. This protection persists for many years even after discontinuing the medication. **Analysis of Incorrect Options:** * **Unopposed Estrogen:** This is the most significant risk factor. Conditions like PCOS, estrogen-secreting tumors (Granulosa cell tumors), or estrogen-only HRT lead to continuous endometrial proliferation. * **Radiation:** Pelvic radiation (e.g., for cervical cancer) is a known risk factor for developing secondary uterine malignancies, particularly uterine sarcomas and occasionally endometrial carcinomas. * **Tamoxifen therapy:** While Tamoxifen acts as an anti-estrogen in the breast, it acts as a **partial agonist (estrogenic effect)** on the uterus. This stimulates the endometrium and increases the risk of hyperplasia and carcinoma. **High-Yield Clinical Pearls for NEET-PG:** * **Protective Factors:** OCPs, Multiparity, Smoking (decreases estrogen levels, though harmful otherwise), and Physical activity. * **Lynch Syndrome (HNPCC):** The most common inherited susceptibility for endometrial cancer; patients require annual screening biopsies starting at age 35. * **Obesity:** Adipose tissue converts androstenedione to estrone via the aromatase enzyme, leading to high endogenous estrogen levels.

Q: Which of the following statements is NOT true regarding cryosurgery?

Nitrous oxide is the most commonly used cryogen.. ### Explanation **Cryosurgery** is a common outpatient procedure used in gynecology, primarily for treating benign cervical lesions and low-grade Cervical Intraepithelial Neoplasia (CIN). **Why Option D is the Correct Answer (The False Statement):** While Nitrous oxide ($N_2O$) is a frequently used cryogen, it is **not** the most commonly used one in modern clinical practice. **Carbon dioxide ($CO_2$)** is the most commonly used cryogen because it is inexpensive and readily available. Both gases work via the **Joule-Thomson effect**, where rapid expansion of the gas through a small nozzle leads to a significant drop in temperature. **Analysis of Other Options:** * **Option A:** Cryosurgery is relatively painless because the freezing process itself exerts an anesthetic effect on the nerve endings. Therefore, it is typically performed **without anesthesia** in an office setting. * **Option B:** To achieve cellular death (cryonecrosis), the temperature must fall significantly below the freezing point of water. $CO_2$ reaches approximately **-65°C to -78.5°C**, while $N_2O$ reaches **-89°C**. * **Option C:** Cryosurgery is an established **ablative treatment** for CIN (specifically CIN 1 and 2), provided the lesion is small, entirely visible on the ectocervix, and there is no evidence of endocervical involvement or malignancy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Cell death occurs due to intracellular ice crystal formation and microvascular thrombosis. * **Technique:** The "Freeze-Thaw-Freeze" technique is the gold standard to ensure maximum tissue destruction. * **Major Side Effect:** Patients often experience a **profuse, watery vaginal discharge** for 2–4 weeks post-procedure as the necrotic tissue sloughs off. * **Contraindication:** It should never be performed if invasive carcinoma is suspected or if the transformation zone is not fully visible (Type 3 TZ).

Q: What is the most common malignancy of the body of the uterus?

Adenocarcinoma. **Explanation:** **Endometrial carcinoma** is the most common malignancy of the female genital tract in developed countries and the most common malignancy of the **body of the uterus** worldwide. 1. **Why Adenocarcinoma is correct:** The uterine body is lined by the endometrium, which is a glandular epithelium. Therefore, the vast majority (approximately 80-90%) of endometrial cancers are **Adenocarcinomas**, specifically the **Endometrioid type**. These are typically estrogen-dependent and arise from endometrial hyperplasia. 2. **Why other options are incorrect:** * **Adenoacanthoma:** This is a historical term for an adenocarcinoma with squamous metaplasia. While it occurs in the uterus, it is considered a subtype/variant of adenocarcinoma, not the most common primary form. * **Squamous cell carcinoma (SCC):** While SCC is the most common cancer of the **cervix**, it is extremely rare as a primary malignancy of the uterine body. * **Sarcoma:** Uterine sarcomas (e.g., Leiomyosarcoma, Endometrial Stromal Sarcoma) arise from the myometrium or connective tissue. They are aggressive but account for less than 5% of all uterine body uterine malignancies. **NEET-PG High-Yield Pearls:** * **Most common symptom:** Postmenopausal bleeding (PMB). Any PMB must be investigated via endometrial biopsy or D&C to rule out malignancy. * **Risk Factors:** Obesity (most significant), nulliparity, late menopause, and Unopposed Estrogen therapy (PCOS, Granulosa cell tumors, Tamoxifen use). * **Protective Factors:** Combined Oral Contraceptive Pills (COCPs) and smoking (due to decreased estrogen levels, though not clinically recommended). * **Lynch Syndrome (HNPCC):** Associated with a significantly high lifetime risk of endometrial adenocarcinoma.

Q: A nulliparous woman presenting with abnormal vaginal bleeding is found to have abnormal endometrial histological findings. Which of the following is NOT a risk factor for uterine carcinoma?

Late onset of menarche. **Explanation:** The primary driver for the most common type of uterine carcinoma (Type I Endometrioid Adenocarcinoma) is **unopposed estrogen**. Estrogen promotes endometrial proliferation, while progesterone acts as a protective agent by inducing differentiation and shedding. **Why "Late onset of menarche" is the correct answer:** Early menarche (starting periods at a young age) and late menopause increase the total number of ovulatory cycles and the duration of lifetime exposure to estrogen. Therefore, **early menarche** is a risk factor, while **late onset of menarche** is actually a protective factor against uterine carcinoma. **Analysis of Incorrect Options:** * **Endometrial Hyperplasia:** Specifically, atypical hyperplasia is a direct precursor to endometrial cancer. Complex atypical hyperplasia carries a nearly 30% risk of progression to malignancy. * **Obesity:** This is a major risk factor. In obese postmenopausal women, adipose tissue contains the enzyme **aromatase**, which converts adrenal androgens (androstenedione) into estrone (estrogen), leading to chronic unopposed estrogen levels. * **Tamoxifen:** While it acts as an anti-estrogen in the breast, it has a **pro-estrogenic (agonist) effect** on the endometrium, increasing the risk of hyperplasia and carcinoma. **High-Yield Clinical Pearls for NEET-PG:** * **PCOS and Nulliparity:** Both are significant risk factors due to chronic anovulation (lack of progesterone). * **Lynch Syndrome (HNPCC):** The most common genetic predisposition; these patients require prophylactic hysterectomy by age 40–45. * **Protective Factors:** Combined Oral Contraceptive Pills (COCPs), smoking (decreases estrogen levels, though not recommended), and multiparity. * **Most common histological type:** Endometrioid adenocarcinoma.

Question 1

A 35-year-old pregnant patient is at the highest risk for the concurrent development of which of the following malignancies?

Accepted Answer

Cervix

Answer

Ovary

Answer

Uterus

Answer

Vagina

Question 2

What are the advantages of hysterectomy in molar pregnancy?

Accepted Answer

Chance of pulmonary embolisation is minimal

Answer

Chance of choriocarcinoma becomes nil

Answer

Follow up is not required

Answer

Enlarged ovaries can be removed during operation

Question 3

A 18-year-old, sexually active female has no family history of cancer or cardiac disease, and her physical examination is unremarkable. Which of the following screening tests would most benefit this patient?

Accepted Answer

Pap smear

Answer

Colonoscopy

Answer

Mammography

Answer

Pelvic scan

Question 4

A 25-year-old woman, 15 weeks pregnant, presents with uterine bleeding and passage of a small amount of watery fluid and tissue. Her uterus is found to be much larger than estimated by her gestational dates. Ultrasound reveals the uterus is filled with cystic, avascular, grapelike structures that do not penetrate the uterine wall. No fetal parts are visualized. What is the most likely diagnosis?

Accepted Answer

Complete hydatidiform mole

Answer

Partial hydatidiform mole

Answer

Invasive mole

Answer

Placental site trophoblastic tumor

Question 5

What is the most common malignant ovarian tumor in young individuals?

Accepted Answer

Dysgerminoma

Answer

Dermoid cyst

Answer

Mucinous cystadenoma

Answer

Fibroma

Question 6

A 50-year-old nulliparous, diabetic, and obese woman presents with post-menopausal bleeding. What is the most likely diagnosis?

Accepted Answer

Endometrial carcinoma

Answer

Carcinoma in situ of cervix

Answer

Dysfunctional uterine bleeding (DUB)

Answer

None of the above

Question 7

All of the following may predispose to Endometrial Carcinoma, except:

Accepted Answer

Oral contraceptive

Answer

Unopposed Estrogen

Answer

Radiation

Answer

Tamoxifen therapy

Question 8

Which of the following statements is NOT true regarding cryosurgery?

Accepted Answer

Nitrous oxide is the most commonly used cryogen.

Answer

It can be performed without anesthesia.

Answer

The temperature used is below the freezing point of water.

Answer

It is a treatment option for cervical intraepithelial neoplasia (CIN).

Question 9

What is the most common malignancy of the body of the uterus?

Accepted Answer

Adenocarcinoma

Answer

Adenoacanthoma

Answer

Squamous cell carcinoma

Answer

Sarcoma

Question 10

A nulliparous woman presenting with abnormal vaginal bleeding is found to have abnormal endometrial histological findings. Which of the following is NOT a risk factor for uterine carcinoma?

Accepted Answer

Late onset of menarche

Answer

Endometrial hyperplasia

Answer

Obesity

Answer

Tamoxifen

Gynecologic Oncology — MCQs

Gynecologic Oncology — MCQs

On this page

Practice by Chapter

Want unlimited practice?